Baxter International Inc. filings document formal disclosures for a NYSE-listed medtech issuer with common stock and listed global notes. Recent 8-K reports furnish earnings releases, financial-condition updates, dividend declarations, Regulation FD stockholder-engagement materials, executive leadership changes, severance and change-in-control arrangements, and exhibits tied to material corporate actions.
The company’s proxy materials cover board governance, stockholder voting matters, executive compensation and pay-versus-performance disclosures. Debt-related filings describe senior note issuances, supplemental indentures, underwriting arrangements and tender offers, while recurring reports identify registered securities, capital-structure actions and governance controls relevant to Baxter’s medical-device and healthcare-products business.
SCHLICHTING NANCY M reported acquisition or exercise transactions in this Form 4 filing.
Baxter International Inc. director Nancy M. Schlichting reported an equity compensation grant of common stock. On May 5, 2026, she received 12,836 fully vested shares of Baxter common stock at a stated price of $0.00 per share, reflecting a grant or award rather than an open-market purchase. Following this grant, her direct holdings increased to 34,994 shares of common stock. The total reported share balance includes the automatic reinvestment of dividends.
MORRISON PATRICIA reported acquisition or exercise transactions in this Form 4 filing.
Baxter International Inc. director Patricia Morrison received a grant of 12,836 shares of common stock on May 5, 2026. The shares were fully vested at grant and awarded at no cash cost per share, as part of the company’s equity compensation. Following this award, she directly holds 42,386 Baxter common shares, a position that reflects both this grant and the automatic reinvestment of dividends.
Shafer David Brent reported acquisition or exercise transactions in this Form 4 filing.
Baxter International Inc. director and Chair of the Board David Brent Shafer received an equity grant of 12,836 fully vested shares of Baxter common stock. The shares were granted at no cash cost to him and are subject to the applicable grant terms and conditions.
Following this award, Shafer directly holds 72,804 Baxter common shares, a figure that includes shares added through the automatic reinvestment of dividends. This filing reflects a compensation-related stock grant rather than an open‑market purchase or sale.
McDonnell Michael R. reported acquisition or exercise transactions in this Form 4 filing.
Baxter International Inc. director Michael R. McDonnell received an equity grant of 12,836 shares of common stock. The award was fully vested when granted and is subject to the terms and conditions of the applicable grant. Following this compensation grant, he holds 14,647 common shares directly.
Craig Jeffrey A reported acquisition or exercise transactions in this Form 4 filing.
Baxter International director Jeffrey A. Craig received an equity grant of 12,836 shares of Baxter common stock on May 5, 2026. The shares were granted at no cost as fully vested stock, subject to the applicable grant terms. Following this award, Craig directly holds 23,662 shares, a figure that also reflects automatic reinvestment of dividends.
Ampofo William A. II reported acquisition or exercise transactions in this Form 4 filing.
Baxter International Inc. director William A. Ampofo II received a stock grant of 12,836 shares of common stock. The shares were granted at no cash cost to him as a fully vested award, increasing his directly held stake to 30,375 shares, including shares from automatic dividend reinvestment.
This Form 4 reflects a compensation-related grant, not an open-market purchase or sale, and does not indicate any change in his trading views on Baxter stock.
Baxter International Inc. — Amendment to Schedule 13G reporting institutional ownership.
FMR LLC (with Abigail P. Johnson disclosed) reports 46,264,804.28 shares of Common Stock, representing 9.0% of the class as of 03/31/2026. The filing shows sole dispositive power for 46,264,804.28 shares and sole voting power of 32,385,962.16 shares. The amendment is signed 05/05/2026 and references an attached Exhibit 99 and a power of attorney.
Baxter International Inc. reported first-quarter 2026 net sales of $2.70 billion, up 3% from $2.63 billion a year earlier, but swung to a net loss of $15 million, or $(0.03) per diluted share, versus net income of $126 million, or $0.25 per share.
Continuing operations posted a loss of $17 million, compared with $64 million of income in 2025, despite higher gross margin dollars. Results were heavily affected by $205 million of special items, including $146 million of intangible amortization and $68 million of restructuring and business optimization charges tied largely to the Kidney Care divestiture.
By segment, Medical Products & Therapies sales rose 2%, Healthcare Systems & Technologies were flat, and Pharmaceuticals grew 7%, driven by strong international drug compounding. However, Novum IQ pump shipment holds, injectables supply constraints, inflationary cost pressures and recall- and hurricane-related items weighed on profitability.
Operating cash flow improved sharply to $213 million from a $99 million use of cash a year ago, helped by working capital improvements. Baxter ended the quarter with $2.02 billion in cash and cash equivalents and $8.62 billion of long-term debt, while continuing multiyear cost-reduction and business transformation programs.
Baxter International reported first-quarter 2026 sales from continuing operations of $2.7 billion, up 3% on a reported basis but down 1% organically, reflecting flat to modestly weaker underlying demand. U.S. sales fell 4% while international sales grew 12% reported and 3% organically.
The company posted a U.S. GAAP net loss from continuing operations of $17 million, or ($0.03) per diluted share, compared with a profit a year ago. Adjusted diluted EPS from continuing operations was $0.36, down 35% from $0.55, as higher tariffs, manufacturing costs and prior-year comparison pressures weighed on results. Baxter’s board declared a quarterly dividend of $0.01 per share and the company reiterated its full-year 2026 outlook, targeting flat to 1% reported sales growth and adjusted diluted EPS of $1.85 to $2.05.
Baxter International Inc reports that Vanguard Capital Management beneficially owns 38,033,907 shares of Common Stock. The filing states this equals 7.36% of the class and that Vanguard has sole dispositive power over 38,033,907 shares and sole voting power over 4,526,932 shares. The filing is a Schedule 13G disclosure of passive ownership.